Merrimack: Fufilling Untapped Potential

Tags

Biopharmaceutical, Cancer, Cure, Defeat, Innovation, Investing, Pancreatic, Pharmaceutical, Research, Solution, Stocks, Technology, Treatment, Trials, Value

Company Description-

Based in Cambridge, Massachusetts, Merrimack Pharmaceuticals (MACK) is a bio-pharmaceutical company that specializes in creating drugs and treatments for cancer. They focus on utilizing innovative technology and research processes to create new drugs that they hope will help patients and eventually lead to cures for cancers. They have a strong belief that one day cancer will be defeated and they hope to be the ones to aid in that victory. Their treatment research specializes in specific cancers and in cancer in general. Merrimack utilizes an interdisciplinary approach to drug discovery and development that enables them to build functional and predictive computational models of biological systems based on quantitative, kinetic, multiplexed biological data.  By thoroughly researching about how cancer adapts and becomes resistant against treatment, as well as how it continues to spur growth, Merrimack hopes to find treatments that can counteract the ways that cancerous cells spread.

Merrimack Workings-

Merrimack currently has six major drugs in clinical development. They also have two major ones in pre-clinical development. Of the six in development, two are in stage two of trials and MM-398 has risen to stage three of trials. Merrimack has an extremely large emphasis on research and has shown significant promise with many of its drugs so far. Besides creating new innovative drugs that Merrimack hopes will lead to cures, they also focus on using current drugs and coupling them with therapeutics to treat cancer and tumor patients as well as possible. Through combining diagnostic and therapeutic combinations, Merrimack attempts to find the best possible treatment for each disease and individual patient.

MM-398

Merrimack’s most successful current drug is MM-398, a drug which is currently in the third phase of clinical trials for its ability to treat tumors resistant to chemotherapy across multiple types of cancers, including lung and prostate cancers. Merrimack believes that they can get a better reaction and response from patients using MM-398 than traditional chemotherapy methods.  The FDA and the European Medicines Agency have now granted MM-398 orphan drug designation in 2011 in metastatic pancreatic cancer which is a massive step for the drug as it begins phase three trials. As Merrimack pushes to the future, MM-398 is a major part of their current trials and they hope it will present itself as a great product in the future of the company and a great way to provide treatments for cancer patients.

Stock Analysis-

Merrimack shows a lot of promise with their new MM-398 drug and other clinical and pre-clinical drugs. However, a great company doesn’t always signify a great stock. In Merrimack’s case however, the potential of the company is represented well by their stock and its value. The Merrimack stock is currently at $6.43 (as of May 2^nd). This is up from $5.50 at the start of the year and up from $4.50 at the end of April. The stock has seen a great rise over the past two days due to recent results reported about their MM-398 trials. In phase three trials, the Merrimack drug MM-398 helped elongate pancreatic cancer patients’ lives two months longer than that of traditional chemotherapy patients. This is a significant success for the company and shows the promise that MM-398 has. The recent success Merrimack has had has led to increased analyst estimates about growth and revenue. The company is expected to grow in sales by 10% this year, and then a whopping 96% in 2015. If analysts are anywhere close to correct with these expectations, the company could expand greatly and see massive increases in revenues and in stock value.  The mean 1 year price target is around $11 dollars which signifies Merrimack could more than double its stock price within the year. Overall, I believe that this is a strong stock with a bright future and thus rate it a buy.  The rise in price may not come in the near future, but there is definite growth available for Merrimack within the next year or two and at some point, their stock price will fully reflect their fantastic potential. Merrimack is a stock that is currently undervalued and has a good chance to reap fantastic gains when their potential is fulfilled and their promising drugs hit the market. 

Cytokinetics – Muscling their Way Up Again

Tags

ALS, Atrophy, Biopharmaceutical, Buy, Degenerative, Investing, Muscle, Paralysis, Research, Stock, Treatment

Company Description-

Cytokinetics, Incorporated (CYTK) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutics. The company utilizes its high level of expertise in the human exoskeleton to try and develop treatments for different diseases. They believe that by using innovative techniques and attempting to create new and innovative therapeutic methods that they can help to bring substantial benefits to patients. The company was started in San Francisco in the late 90’s and have been trying to find new drugs and treatments to help ailing patients ever since. Cytokinetics uses a time tested business strategy in which they minimize potential business risk by creating partnerships and focus on therapeutic development areas in which there are “clinical unmet needs.” This is a company that is trying to create the future of medicinal cytoskeletal pharmacology and bring new and successful treatments to patients.  The company focuses on three main areas of therapeutics: Cardiac Muscle Contractility, Smooth Muscle Contractility, and Skeletal Muscle Contractility. Although all three areas are important and require significant research and time, Skeletal Muscle contractility is a strong point for Cytokinetics as it is an area in which the company attempts to play on their knowledge and expertise in cytoskeletal pharmacology.

Skeletal Muscle Disease-

One of the main focus areas of Cytokinetics is helping people with skeletal muscle issues. They hope to create treatments that will reverse and fight against the clinical effects of muscle weakness and wasting and fatigue. These symptoms can lead to a decreased quality of life and life threatening conditions, as well as death. Cytokinetics hopes to create drugs and treatments that can reverse the effects of these diseases and improve muscle growth and muscle function within patients. This would allow people with diseases such as ALS and Muscular dystrophy the chance to enhanced muscle performance and a better quality of life.

Amyotrophic Lateral Sclerosis (ALS)-

Amyotrophic Lateral Sclerosis (ALS), also commonly known as Lou Gehrig’s disease, is a neurodegenerative disease that affects nerve cells in the brain as well as in the spinal cord. ALS creates the degeneration of motor neurons in the brain, which leads to decreased control of muscles and the inability to use muscles or create muscle movement within the body. Because the brain cannot direct the use of the muscles, the muscles in the body remain unused and begin to atrophy. Although the disease is not all that common, it has a massive impact as it does considerable damage and has no cure or drug that reverses the degeneration. That is where Cytokinetics comes in. Cytokinetics has been working on an ALS drug called “Tirasemtiv” for a couple of years now. The drug passed into phase two of trials in 2011. This drug improves the sensitivity of muscles to calcium, which leads to an increase in muscle growth and delays muscle fatigue. It was revealed very recently that Tirasemtiv failed to significantly outperform the placebo drugs (as rated by the ALS Functional Rating Scale) and struggled to meet secondary endpoints and goals. This negative news led to a massive decline in stock price as CYTK fell from around $13 to $4.59 Friday afternoon in the span of just one day. This is a loss of more than 64%! CYTK may continue to try and test and tweak Tirasemtiv to try and create a more successful ALS drug or they may have to start anew.

Stock Analysis-

Despite the negative news and massive stock price, I believe that Cytokinetics is a buy. You may be highly confused why a stock that dropped 64% is a buy, but you have to look deeper than some recent stock news when evaluating the company. First of all, CYTK has two other main drugs in clinical trials at the moment. They also have partners on both of these drugs as they have pared up with Amgen and Astellas. This partnership ensures increased funding and also guarantees Cytokinetics a huge payout if the drugs come to be successful or pass certain tests.  One drug that Cytokinetics is working with in collaboration with Astellas is CK-107, another drug that aims to help patients with muscle degenerative diseases. This drug is only in phase one, but is backed by strong funding and research and could help to alleviate pain and suffering from patients with degenerative muscle diseases. The company also has seen great growth in recent years. Cytokinetics increased its revenues by a multiple of 4 times from 2012-2103. They also have very strong current and quick ratios which is rare for biopharmaceutical companies. The company is also valued by most analysts and investors at much higher than their current stock price. Out of 7 analysts on Yahoo Finance, the average one year price target is $16.05 and the low is $7, which is $2.50 over the current price. To sum up, the massive price drop is definitely attributable to the recent negative stock news, but was a massive over adjustment for bad news by investors. The stock should have dropped with this news, but not as much as it did. This is a highly undervalued stock and even if the company does not see any drug successes in the near future, their stock should still rise in price.

Arctic Cat: Engineering Their Own Way

Tags

ATV, Earnings, Engines, Innovation, Investing, Partnerships, Production, Snow, Snowmobile, Stocks, Winter

Company Description-

Arctic Cat Inc. (ACAT) is a Minnesota based company that designs, engineers, and manufactures snowmobiles, all-terrain vehicles, and Side by Sides (a type of small off-road vehicle). They also produce accessories and garments. They are one of the most respected and well-known snowmobile brand names and have increased their standing in the ATV market recently as well. The company mainly markets its products within the U.S and Canada, but they also have distributors who represent dealers in international markets within the Middle East, Europe, and Asia.

What changes has the company made recently?-

In 2010, Arctic Cat made a decision to start producing most of its own engines for its snowmobiles. Suzuki had been supplying the company with engines for 25 years and will be continuing to supply support to older model snowmobiles, but will slowly be phased out as Arctic Cat plans to start production of their snowmobile engines in 2015 at a facility they already possess in St. Cloud, Minnesota.  By doing this, they hope to gain more control over their production and costs, as well as better utilize their resources. The St. Cloud facility has been a location where Arctic Cat has produced their ATV engines since 2007, and thus there is quite a bit of machinery already located there which will help to cut down on switching costs. They also have not been operating at full capacity so this should also cut down on wasted space and cost. The company has many skilled engineers in St. Cloud who have been creating ATV engines for years and should have minimal problems in switching to snowmobiles.

So why the change?-

Many people were taken back at the decision that Artic Cat made on dropping Suzuki as engine supplier and deciding to make their own. Suzuki is one of the most popular and most successful brand names in extreme sports and has a fantastic reputation within this community. So why make this decision now after 25 years of working together? As mentioned previously, this is an opportunity to lower costs and gain more control over operations. One problem that Arctic Cat had experienced in their relationship with Suzuki was that Suzuki has not wanted to utilize the kind of technology that Arctic Cat wanted and instead have stuck to their traditional models. Arctic Cat facilities have a reputation for being highly efficient and using innovative technology in producing snowmobiles, ATV’s and the engines that they have produced. This may be Arctic Cat’s way of announcing that they want to step up their game a little and produce their engines the way they want them to be produced. Whereas suppliers may have been reluctant to try new things as they would not want to incur potential R&D costs that may have come, Arctic Cat is ready and trying to attempt new things and use new technologies in order to improve their companies’ image and create a stronger and better product.

Recent earnings report-

Arctic Cat is currently sitting at a stock price of around $43. This is well below the high price in March of about $49 and substantially lower than the price of $55 that the company peaked at in early January.  Why has it gone down so much in such a short time? Some of the drop can be contributed to the recent problems in the stock market, but the answer lies in the recently reported earnings statements. Arctic Cat’s numbers were very disappointing and they missed their overall goals as well as their snowmobile goals by quite a lot. Claude Jordan, the CEO of Arctic Cat believes that the poor results were due in some part to economic issues in Europe, and also due in part to lower gross margins on snowmobiles as a result of a recent partnership with Yamaha in the snowmobile sector. The company also lowered their expected growth and sales numbers for 2014 after the reports which led to a further drastic selloff of the stock by investors.  Although the poor numbers were a definite setback for Arctic Cat, I do not believe they are a harbinger of things to come.  Record snowfalls this winter set the stage for increased snowmobile sales and the production of engines in the St. Cloud facility will lead to lower costs and possibly lower prices for snowmobiles. The company has also been making some strategic moves to grow their off-road vehicle segment and increase their market share within the segment.

Stock Analysis-

Personally I think that this is a fantastic stock with great potential. However, they may not have reached their potential just yet and it may be some time before they do so.  That being said, I still believe that they should be a buy as they are very undervalued at this point in time. The company’s revenue and gross profit growth has been steadily increasing and they have a very strong current ratio. They also are very effective and have high ROE’s and ROA’s year after year. Analyst estimates are also very favorable for the company as their stock price is considered quite undervalued at the moment. The consensus of most analysts is that the stock should be rated a buy and that its value at the very least should be in the upper $40’s.  Their poor earnings report led to a giant selloff but consumers likely overreacted and the stock should see a rise relatively soon. Whether it will rise back to where it was at the start of January in the near future or whether it may take longer is debatable, but one thing is certain: $43 is not the highest price that this stock will see.  If you are an investor looking for massive gains in the near future, then Arctic Cat may not be the investment choice for you, but for patient investors who believe in the future of this company, this stock could bring some decent returns to a portfolio.

 

2U: Educating the Online Masses

Tags

Classes, Cloud Services, College, Education, Future, Online, Technology, University

Company Description-

2U Inc. (TWOU) is a company that offers technologically based online classes while partnering with some of the best colleges and universities in the world. They are a relatively new company and were founded in 2008 by a team consisting of education professionals and technology people. They use cloud based software as a service platform in order to make their online classes interactive and discussion based. They believe that by brining students together on the cloud during classes, they can initiate deeper thinking during online classes and lead to a stronger form of online learning. Even though they have been in operation since 2008, they only recently became public and had their IPO on March 28^th.

What are these online programs and what differentiates them from competition?-

Nearly every school offers online courses and classes to its students and numerous other companies offer simple online classes if you want to get classes done and out of the way. So what makes 2U better? 2U prides itself on its relationship with universities, its usage of new technology and cloud platforms, and its ability to bring interesting and challenging classes to students. First off, 2U partners with well-known educational institutions such as UNC, Notre Dame, University of Washington St. Louis, and Boston College. In partnering with these universities, the online classes that 2U offers, are the same courses that are taught at these universities. When students take a UNC class with 2U, they take the same course taught at UNC and even are taught by the exact same UNC professor. This gives students the chance to take an interesting highly accredited course from a highly educated and renowned teacher. Besides the interesting course, students also have a chance to take advantage of the company’s innovative use of technology. Students log into an online platform using video cameras and microphones and are placed in an online classroom with their fellow classmates and teachers also on camera. This gives the advantage of making the classes interactive and discussion based as compared to traditional online classes. By making it interactive, 2U gives the students the chance to discuss and learn more like they would in an actual in classroom course. This also allows the student to challenge themselves more and really put their brain to use in discussing these interesting subjects with others in the class.

Stock Analysis –

Since their initial IPO offering at $13, rose to about $15.50 before falling back towards the $13 mark. So what does 2U’s future hold? At this point it is relatively hard to say. Because they have only recently become public, there is not a whole lot of financial data out there for the company and stockholders are still struggling at this point to look into their future and see what it holds financially. Because they are relatively new they are putting a lot of money into R&D costs and are doing all they can to utilize their technology to make their cloud based platform attractive and easy to use. Because of their lack of financial data it is rather difficult to give the company a rating at this point. They are a highly innovative company and have seen decent growth within the last couple of years but are still a relatively new company. However, with the explosion of the online education market, 2U has a lot of growth opportunities available if they should be able to keep on expanding and improving. At this point I would rate the company a hold based on their lack of financial data and relatively new stake in the public markets. However, I believe that they are a company that has high potential and can use their innovation using technology to really propel themselves to great heights. Investors should keep a keen eye on this company as they have the potential to really make something great out of themselves.

Summary-

2U’s use of innovative technology in offering cloud-based classes combined with their partnership with highly accredited universities is helping to establish them as a top-notch online education company. Their ability to differentiate from their competition shows that they have the ability to stand out in an increasingly saturated market and will continue to do so. Although there is not much financial data available on the company at the moment, they have a lot of promise in their future and have the potential to explode forward as a stock and as a company. They may not be a huge name at the current time, but if the company continues to innovate and establish itself within the educational world, they have the chance to be a very successful company and take a large percentage of the market share within the online education market.

Alexion Pharmaceuticals: Innovation For the Future

Tags

Blood Cells, Innovation, Investing, Medicine, Money, Pharmaceuticals, Soliris, Treatment

Company Description-

Alexion Pharmaceuticals is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Through their innovative production of therapeutic products such as Soliris, they hope to treat patients with diseases such as Atypical Hemolytic Uremic Syndrome (a genetic disease in which a deficiency in certain genes affects kidney function) and Paroxysmal Nocturnal Hemoglobinuria (a very rare blood disorder which can lead to the destruction of red blood cells). People with these two diseases often have no treatment options at all, but Alexion’s Soliris gives hope to families who have loved ones battling PHS or AHUS and elongates patients’ lives. Alexion is a fantastic company who is doing their best to change the world, and they have been rewarded by being named # 2 on Forbes list of most innovative companies for the second year in a row.

What is Soliris and why is it so great?-

So what is Soliris? Soliris is the “world’s first and only approved terminal complement inhibitor,” which means that it helps the patient by preventing the body from attacking and destroying red blood cells. Red blood cells are of vital importance to the human body as they deliver oxygen throughout the body and help keep vital organs healthy. Without red blood cells parts of your body can not function correctly and can lead to extreme tiredness, and loss of function within certain parts of the body (such as the kidneys). In preventing the destruction of these blood cells, Soliris helps to keep red blood cells at a normal level within patients who struggle with diseases such as PNH. The main cause of serious health problems with PNH is hemolysis, which is the popping of red blood cells. Treatment using Soliris leads to a decrease in Hemolysis; a decrease in blood clots within patients, and leads to a much lower need for blood transfusions within patients.  Without the aid of Soliris, PNH patients require constant blood transfusions in order to replenish their depleted red blood cell count.

The other disease that Soliris helps to treat is Atypical Hemolytic Uremic Syndrome (AHUS). This is a genetic disease which causes blood clots to form in small blood vessels within the kidneys. These clots can lead to kidney failure if they restrict or stop blood flow. It can also cause hemolysis within the blood stream. It also causes Thrombocytopenia, which is when there is a deficiency of platelets within the blood stream because the platelets are stuck and causing blood clots. As mentioned previously, Soliris can help to reduce red blood cell loss and can increase the flow of blood within the body. It prevents blood clots and keeps the organs throughout the body functioning normally.

Stock Analysis-

Alexion Pharmaceuticals is a fantastic company that is a world leader in innovation and is creating waves throughout the medical field. But is it worth investing in? Alexion (ALXN) is currently trading at $150 although it opened today at $153 and was as high as $180 just a few weeks ago. So why has it dropped so significantly in the last two weeks? Some people think that the stock was just falling down to earth as it had previously increased its price from $130 at the start of 2014 to the high of $183.89 that it hit on February 27^th. The initial increase was due in large part to good earnings reports for the last quarter combined with the fact that its earnings growth prediction for this year alone is over 40%. This stock has great potential for growth and investors believe it is just a matter of time before it takes off. With great innovation and a high potential for growth I definitely believe that this stock is a strong buy. The company’s revenues have grown more than 30% each of the past two years and that trend is expected to continue. They are also maintaining a lot of their earnings and creating substantial net income, which is not a common thing for pharmaceutical companies who tend to have extremely high R&D costs.  The company’s balance sheet is also extremely strong as the increase in assets over the last three years is much greater than the increase in liabilities.

Summary-

Alexion Pharmaceuticals is a company that has seen excellent growth as of recent and will continue to see this growth in the near future. They are a world leader in innovation and are making a difference in the medicinal world. With their fantastic Soliris product, they are helping to treat patients with rare and dangerous diseases and are giving hope to families who have loved ones battling these diseases.  At the current price of $150, ALXN is a definite buy and will reap great returns in the future. The high point of $184 that Alexion hit in February was a great step for the company, but based on their growth potential and innovative history, is likely not the highest that Alexion will rise to. If you are looking for a pharmaceutical company that will change the future, and possibly the thickness of your wallet, you should take a serious look at Alexion Pharmaceuticals.

Mast Therapeutics: Increasing Blood Flow and Investors’ Income?

Tags

Blood Flow, Disease, Investing, Medicine, Sickle Cell Anemia, Stocks, Therapeutics, Therapy, Treatment

Company Description-

Mast Therapeutics (MSTX) is a biopharmaceutical company based in San Diego that focuses on creating therapies and treatments for serious or life threatening diseases and illnesses such as strokes, sickle cell anemia, and heart failure. Mast Therapeutics main focus is working on their MST-188 product, but they also have many other developmental drugs and therapies in the works.

What is MST-188-

Mast Therapeutics strongest current product, MST-188, is an investigational agent that can be used in the treatment of many different kinds of diseases and conditions. MST-188 is mainly used in treating patients who have diseases which lead to weakened blood flow and/or imbalances within the inner lining of blood vessels. This can ultimately lead to circulation problems and can weaken the immune system.  One example of such a disease is sickle cell anemia, a hereditary blood disease that can slow the flow of blood and lead to organ damage and death.  MST-188 is currently being used in a therapy and treatment study of sickle cell patients and has recently proven to increase blood flow within patients and also reduce inflammation that could lead to pain or organ damage.  MST-188 is also being used in treating other diseases by attempting to reduce or eliminate blood clots within the body and by increasing the blood flow and circulation of the patients.

Stock Analysis-

At the current moment in time, I do not believe that MSTX is a stock that is worth buying. It is currently priced at $0.70 although it was priced as high as $1.05 in mid-January. Earnings reports that came out yesterday have shown that the company had higher losses in the fourth quarter of 2013 than it did in 2012. This is obviously not what the stockholder wants to hear, but in the bio-pharmaceutical sector losses are quite common for relatively new companies due to extremely high R&D costs. However, MSTX has a lot of drugs in the works and has shown promise with the success of its MST-188 agent. As other stocks have proven within this sector, it only takes one successful drug to propel a company upwards. Due to the size of the company, MSTX has a high volatility and high beta.   The market cap for MSTX is slightly above 71.64 million which means that Mast Therapeutics counts as a micro-cap stock. It also has a fairly low daily trading volume which means that any surge in trading could easily increase the price of the stock. If any one of these drugs were to prove highly successful, MSTX could see a massive surge in the stock price. Although at the current point in time MSTX is not a stock I would rate as a buy, it is definitely a company with great potential that could hit its stride at any point. This should be a company that investors keep an eye on in the news and take note of as it could potentially hit it big in its search for improved therapeutic solutions.

Summary-

Overall, Mast Therapeutics is a company that has not yet reached its potential. In its search for therapeutic solutions it is spending a lot on research and development and working to find its go to drug. When this will happen is a definite unknown, but when it does, MSTX will quickly increase its price and become a stock that investors will jump on. MSTX’s main drug at the moment is their MST-188 agent which is helping to increase blood flow and decrease clots in patients with serious and life threatening diseases. This is a company that is trying to save the world and has the research and people to do it. The company may not be the next Gilead Sciences, but one thing is for certain; they have not yet reached their best!

 

IsoRay Inc: Stocking Up On the Future of Cancer Treatment

Tags

Brachytherapy, Cancer, Innovation, Investing, Isotopes, Mesh, Radiotherapy, Small-Cap, Treatment

Company Description-

IsoRay Inc. (ISR) is a company that is really doing some interesting things as of late. IsoRay as a company utilizes proprietary technologies to deliver new and different brachytherapy approaches to clinicians. Brachytherapy is a new form of radiotherapy in which radioactive materials are temporarily inserted directly into tumors or by cancerous tumors in the body.  By doing this, it is ensured that the tumor receives the most effective dose of radiation to kill the cancerous cells. IsoRay is in the business of killing cancer; a business that is well supported throughout the world and will continue to see increased investment and support.

So why does IsoRay gauge my interest?

This is a company that is revolutionizing the brachytherapy business. They are creating new isotopes and ways to defeat the dreaded disease which is cancer.  IsoRays Cesium-131 isotope has been dubbed as possibly “the most significant scientific advancement in cancer brachytherapy in more than 20 years.” This isotope has been used as primary treatment for prostate cancer in over 7,000 patients and is also being used as a secondary treatment method in attempting to manage non-small cell lung cancer, intra-cranial tumors,  and head & neck malignancies post-surgical resection. Overall, the Cesium-131 isotope provides a powerful and new radiation treatment with a successful track record.

But really, whats so great about Cesium-131?

IsoRay as a stock has seen some heavy volatility over the last couple days due to an overly zealous initial response to great news within the recent week. On March 11th IsoRay announced that the Greek Government approved sales for a product line within the country. However, the news that probably gave way to the sudden rise was that a doctor in North Carolina successfully completed the world’s FIRST pediatric implant using IsoRay Medical’s Cesium-131 brachytherapy mesh. The patient was a 12 year old boy who had a type of childhood kidney tumor in his chest. He had been treated before for this but the cancer had returned.  Not only was the operation successful, but the company was able to produce the mesh in under a week.  With the use of the Cesium-131 mesh, doctors were able to get the optimal dosage to the area which they needed to reach to most effectively destroy the cancerous cells.

Stock Analysis –

After this news was spread, IsoRay saw a massive surge in its stock price, rising from a $1.09 closing price on March 18 to a closing price of 2.55 the next day. This represents an increase in price of over 130 percent. The stock also surged the next day reaching as high as $3.77 before investors brought the stock down to earth today dropping it back to about its current price of $2.50.  So why will this stock be successful in the future? Well first of all as previously stated it is revolutionizing the cancer treatment industry. It has support of cancer survivors and haters everywhere and has a multitude of private investors bowing at their feet.  Public investors have not been as interested due to relatively disappointing revenue numbers and growth, but companies with high research and development costs such as IsoRay often struggle to get off the ground and get their revenues higher. However, this company has been increasing its cash flows for the last couple of years and has a strong balance sheet with very low debt ratios. Growth has been slow if not negative over the last year but analysts now expect the company to grow greatly towards the end of 2014 and see massive growth in 2015.

Summary-

As a company IsoRay is increasing the size of their business and working to save the lives of millions of cancer patients around the world. Using new technologies such as their Cesium-131 isotope, they are helping to revolutionize the brachytherapy industry and improve cancer survival rates. As a stock IsoRay is likely fairly valued at about $2.50 at the current time, but as the company continues to grow and produce these innovate and novel technologies, their brand name and their stock price will grow. With a future so bright and a product that is already helping doctors to do great things, IsoRay has an extremely bright future. As a company who is revolutionizing the way we treat cancer and cancerous tumors, IsoRay is definitely ahead of the game.